IL-2 infusion abrogates humoral immune responses in humans
- PMID: 1544235
- PMCID: PMC1554326
- DOI: 10.1111/j.1365-2249.1992.tb03025.x
IL-2 infusion abrogates humoral immune responses in humans
Abstract
Although IL-2 infusion enhances cell-mediated cytotoxicity in patients with neoplastic disease, administration is paradoxically associated with a modest fall in total serum IgG and an increased risk of infection. We now show that the adverse effects of IL-2 infusion on the humoral immune system are substantial. Although IL-2 induces the B cell growth and differentiating factors IL-4 and IL-6, infusion abrogates primary antibody responses entirely and reduces secondary antibody responses 50-fold following antigen challenge. There is no evidence of the generation of cells with suppressive activity on B cells but IL-2 increases the ratio of circulating virgin:memory cells. These results may help to explain the increased rate of bacterial infection in patients receiving IL-2. As IL-2 plays a central role in the generation of an immune response, the finding that it is also sufficiently immunosuppressive to inhibit primary- and secondary-type antibody responses suggests that exploration of the underlying mechanisms may provide insights into immune system homeostasis and may offer new approaches to therapeutic immunosuppression.
Similar articles
-
Peripheral blood and bone marrow immunophenotypic and functional modifications induced in acute leukemia patients treated with interleukin 2: evidence of in vivo lymphokine activated killer cell generation.Cancer Res. 1991 Feb 1;51(3):964-8. Cancer Res. 1991. PMID: 1988139
-
Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.Leukemia. 1992 Aug;6(8):780-5. Leukemia. 1992. PMID: 1640729
-
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.Leuk Lymphoma. 1997 May;25(5-6):469-78. doi: 10.3109/10428199709039034. Leuk Lymphoma. 1997. PMID: 9250817 Clinical Trial.
-
Understanding the mechanism of cure of acute myeloid leukemia by allogeneic bone marrow transplantation: toward the application of interleukin-2 in autologous bone marrow transplantation.J Hematother. 1994 Spring;3(1):47-50. doi: 10.1089/scd.1.1994.3.47. J Hematother. 1994. PMID: 7922008 Review.
-
Current thinking in the management of leukaemia.Aust Fam Physician. 1994 Aug;23(8):1500-5. Aust Fam Physician. 1994. PMID: 7526835 Review.
Cited by
-
Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy.Clin Exp Immunol. 1994 Feb;95(2):232-6. doi: 10.1111/j.1365-2249.1994.tb06516.x. Clin Exp Immunol. 1994. PMID: 8306497 Free PMC article.
-
Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.Clin Cancer Res. 2014 Apr 15;20(8):2215-25. doi: 10.1158/1078-0432.CCR-13-3205. Epub 2014 Feb 26. Clin Cancer Res. 2014. PMID: 24573552 Free PMC article. Clinical Trial.
-
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.Drugs. 1993 Sep;46(3):446-514. doi: 10.2165/00003495-199346030-00009. Drugs. 1993. PMID: 7693434 Review.
-
Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.Cancer Immunol Immunother. 1995 Jan;40(1):37-47. doi: 10.1007/BF01517234. Cancer Immunol Immunother. 1995. PMID: 7530170 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials